Yuhan Corporation

A000100

KR7000100008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 2024-09-20			5-day change	1st Jan Change
145,400.00 ^KRW	+15.86%		+16.51%	+111.34%

08-22	South Korean Shares Rise After BOK Rate Hold; Yuhan Gains on FDA Approval	MT
08-22	Yuhan Shares Jump 4% After US FDA Approves Anti-Cancer Drug for US Markets	MT

Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.

July 29, 2024

On July 30, 2024, the company announced that it has extended its plan duration till July 31, 2025.

Latest news about Yuhan Corporation

South Korean Shares Rise After BOK Rate Hold; Yuhan Gains on FDA Approval	08-22	MT
Yuhan Shares Jump 4% After US FDA Approves Anti-Cancer Drug for US Markets	08-21	MT
Yuhan Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-14	CI
Aimed Bio Inc. announced that it has received KRW 40 billion in funding from Samsung Venture Investment Corporation, DS Asset Management Co., Ltd, Yuhan Corporation, InterVest Co., Ltd., Mint Venture Partners	07-30	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.	07-29	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.	07-29	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.	07-29	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.	07-29	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.	07-29	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.	07-29	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.	07-29	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.	07-29	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.	07-29	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.	07-29	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2025.	07-29	CI
Yuhan Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI
Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	04-24	MT
Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Progen Co., Ltd. announced that it has received KRW 9.71405799 billion in funding from Yuhan Corporation and other investors	02-07	CI
COSON Co., Ltd. announced that it expects to receive KRW 3 billion in funding from Cruise Holdings Co., Ltd., Yuhan Corporation and other investors.	12-28	CI
Yuhan Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million.	11-02	CI
Contagion fears spread as China property sector cash crunch intensifies	23-08-14	RE
Yuhan Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Country Garden shares dive after bond trading halted, fans further economic distress	23-08-13	RE

Yuhan Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and Health segment is involved in the production and sale of household goods and animal healthcare (AHC) products, including bleach, antibacterial agents. The Overseas Business segment supplies raw drugs to domestic and overseas markets. The Company also sells licenses. The Company distributes its products in domestic and overseas markets such as Europe, Asia and United States.

Employees

1,999

Sector

Pharmaceuticals

Calendar

2024-11-12 - Q3 2024 Earnings Release (Projected)

More about the company